Soluble urokinase plasminogen activator receptor in patients with abdominal aortic aneurysm.
BACKGROUND
In the present study we investigated the impact of soluble urokinase plasminogen activator receptor (suPAR) as a biomarker in patients with abdominal aortic aneurysm (AAA) in relation to conventional inflammatory markers, aneurysm size, and rupture.


METHODS
suPAR and conventional inflammatory markers were measured in 119 patients with AAA and 36 controls without aneurysm matched by age, gender and smoking habit.


RESULTS
The results support earlier studies suggesting a state of activated inflammatory response in patients with nonruptured AAA as expressed by elevated CRP and IL-6 compared with the controls. In contrast, suPAR showed similar levels in patients with nonruptured AAA compared with the controls. Unexpectedly, all follow-up patients (n=16) have significant (p<0.001) elevated suPAR levels three years postoperatively compared preoperatively.


CONCLUSIONS
suPAR does not seem to be a useful biomarker in the AAA disease. The role of the postoperative elevation of suPAR needs to be further elucidated.
Department of Clinical Chemistry, Sundsvall County Hospital, Sweden. markus.lindqvist@lvn.se
Markus
M
Lindqvist
Jonas
J
Wallinder
Anders E
AE
Henriksson
D000368:Aged; D017544:Aortic Aneurysm, Abdominal / Q000097:blood / Q000201:enzymology* / Q000453:epidemiology*; D015415:Biomarkers / Q000097:blood / Q000737:chemistry; D005260:Female; D006801:Humans; D008297:Male; D015995:Prevalence; D055293:Receptors, Urokinase Plasminogen Activator / Q000097:blood* / Q000737:chemistry; D015203:Reproducibility of Results; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D012995:Solubility; D013548:Sweden
D015415:Biomarkers; C524898:PLAUR protein, human; D055293:Receptors, Urokinase Plasminogen Activator